Systems Pharmacology to Investigate the Interaction of Berberine and Other Drugs in Treating Polycystic Ovary Syndrome

Overview

Journal Sci Rep

Specialty Science

Date 2016 Jun 17

PMID 27306862

Citations 17

Authors

Yu Wang

Xin Fu

Jing Xu

Qiuhong Wang

Haixue Kuang

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is a common multifactorial endocrine disorder among women of childbearing age. PCOS has various and heterogeneous clinical features apart from its indefinite pathogenesis and mechanism. Clinical drugs for PCOS are multifarious because it only treats separate symptoms. Berberine is an isoquinoline plant alkaloid with numerous biological activities, and it was testified to improve some diseases related to PCOS in animal models and in humans. Systems pharmacology was utilized to predict the potential targets of berberine related to PCOS and the potential drug-drug interaction base on the disease network. In conclusion, berberine is a promising polypharmacological drug for treating PCOS, and for enhancing the efficacy of clinical drugs.

Citing Articles

Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs.

Malik S, Saeed S, Saleem A, Khan M, Khan A, Akhtar M Front Endocrinol (Lausanne). 2024; 14:1294406.

PMID: 38725974 PMC: 11081130. DOI: 10.3389/fendo.2023.1294406.

Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment.

Zhao H, Zhang J, Cheng X, Nie X, He B J Ovarian Res. 2023; 16(1):9.

PMID: 36631836 PMC: 9832677. DOI: 10.1186/s13048-022-01091-0.

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.

Behl T, Singh S, Sharma N, Zahoor I, Albarrati A, Albratty M Molecules. 2022; 27(12).

PMID: 35744831 PMC: 9229453. DOI: 10.3390/molecules27123705.

Metabolic Surgery on Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Yue W, Huang X, Zhang W, Li S, Liu X, Zhao Y Front Endocrinol (Lausanne). 2022; 13:848947.

PMID: 35360056 PMC: 8961297. DOI: 10.3389/fendo.2022.848947.

Transcriptome comparative analysis of ovarian follicles reveals the key genes and signaling pathways implicated in hen egg production.

Sun X, Chen X, Zhao J, Ma C, Yan C, Liswaniso S BMC Genomics. 2021; 22(1):899.

PMID: 34911438 PMC: 8672471. DOI: 10.1186/s12864-021-08213-w.

References

Yamada K, Yuan X, Ichikawa F, Nonaka K . Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia. 1999; 42(1):98-101. DOI: 10.1007/s001250051120. View

Balen A . Pathogenesis of polycystic ovary syndrome--the enigma unravels?. Lancet. 1999; 354(9183):966-7. DOI: 10.1016/S0140-6736(99)00218-4. View

Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R . Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002; 26(7):883-96. DOI: 10.1038/sj.ijo.0801994. View

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

Nelson-Degrave V, Wickenheisser J, Hendricks K, Asano T, Fujishiro M, Legro R . Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol. 2004; 19(2):379-90. DOI: 10.1210/me.2004-0178. View

Hamosh A, Scott A, Amberger J, Bocchini C, McKusick V . Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2004; 33(Database issue):D514-7. PMC: 539987. DOI: 10.1093/nar/gki033. View

Vrbikova J, Cibula D . Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update. 2005; 11(3):277-91. DOI: 10.1093/humupd/dmi005. View

Spencer-Jones N, Wang X, Snieder H, Spector T, Carter N, ODell S . Protein tyrosine phosphatase-1B gene PTPN1: selection of tagging single nucleotide polymorphisms and association with body fat, insulin sensitivity, and the metabolic syndrome in a normal female population. Diabetes. 2005; 54(11):3296-304. DOI: 10.2337/diabetes.54.11.3296. View

Wishart D, Knox C, Guo A, Shrivastava S, Hassanali M, Stothard P . DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2005; 34(Database issue):D668-72. PMC: 1347430. DOI: 10.1093/nar/gkj067. View

10.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11):4237-45. DOI: 10.1210/jc.2006-0178. View

11.

Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F . Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007; 92(7):2500-5. DOI: 10.1210/jc.2006-2725. View

12.

De Leo V, Morgante G, Piomboni P, Musacchio M, Petraglia F, Cianci A . Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007; 88(1):113-7. DOI: 10.1016/j.fertnstert.2006.11.137. View

13.

Escobar-Morreale H, San Millan J . Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007; 18(7):266-72. DOI: 10.1016/j.tem.2007.07.003. View

14.

Norman R, Dewailly D, Legro R, Hickey T . Polycystic ovary syndrome. Lancet. 2007; 370(9588):685-97. DOI: 10.1016/S0140-6736(07)61345-2. View

15.

Imanshahidi M, Hosseinzadeh H . Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008; 22(8):999-1012. DOI: 10.1002/ptr.2399. View

16.

Schneider G, Hartenfeller M, Reutlinger M, Tanrikulu Y, Proschak E, Schneider P . Voyages to the (un)known: adaptive design of bioactive compounds. Trends Biotechnol. 2008; 27(1):18-26. DOI: 10.1016/j.tibtech.2008.09.005. View

17.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

18.

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A . ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25(8):1091-3. PMC: 2666812. DOI: 10.1093/bioinformatics/btp101. View

19.

Baxter J, Webb P . Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009; 8(4):308-20. DOI: 10.1038/nrd2830. View

20.

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View